Oncology and Immuno-oncology Assays

Test the efficacy of your oncology-targeted compound in vitro in a rapid, reliable, and cost-effective way.

Our range of cancer cell-based assays include patient-derived xenograft (PDX) assays and assays representing the entire tumor microenvironment (TME), so that your therapies are not only tested for their effect on real patient materials but also their interaction with human immune systems.


Image of tumor for AACR 2021 signifying the oncology research done at Charles River

AACR Annual Meeting 2021

No matter the circumstances, cancer patients are waiting on new therapies. Browse this year's collection of scientific posters and resources so your oncology research can continue moving forward.

Keep Moving Forward


Translational PDX Assays

Our proprietary cell lines are available as “matched pairs,” i.e., cell lines and corresponding patient-derived xenografts (PDXs), and can be used 2D in vitro, 3D ex vivo, and in vivo PDX, with a seamless transition between assays.

With 80 proprietary cell lines derived from our portfolio of PDX models and over 200 commercial human tumor cell lines available, we offer you the opportunity to test your compound with an extensive screening approach for up to 50 cell lines. In addition to selected clinical data and comprehensive molecular data for the originating tumor model, these cell lines are also characterized by their sensitivity for up to 240 reference agents.

Standard or custom screening panels are available and span a wide variety of cell types.

 


Cancer cells used for immuno-oncology assays

Webinar: Catching Patient Diversity In Vitro

Discover how scientists are using PDX cancer cell-based assays to optimize oncology research approaches and help us understand treatment efficacy.

Watch the Webinar


Translational Immuno-Oncology Assays

Given the complexity of the tumor microenvironment, it is imperative to create in vitro immuno-oncology assays that include all major immune cell types a compound may interact with. Investigating with a multicellular phenotypic assay enables us to examine a compound’s responses in platforms specifically designed to mimic the tumor microenvironment.

Optimized cancer cell-based assays provide critical information to validate the efficacy of a compound in simple and increasingly complex co-culture assays.

The Impact of the Tumor Microenvironment

 
 

Rhiannon Jenkinson, Director of Science at Charles River, discusses the impact of the tumor microenvironment on immune-oncology drug development.

Starting with T cell modulation, we can monitor T cell activation, T cell proliferation, T cell exhaustion, T cell chemotaxis, and cytokine response. We have also developed single cell and co-culture assays to monitor an immunotherapeutic’s interaction with specific cell types such as natural killer cells, macrophages, dendritic cells, neutrophils, and fibroblasts.

Available as both 2D and 3D, the oncology assays deliver insights that serve as better predictors for the transition to in vivo studies.


DS-cell-based-assays-for-the-tumor-microenvironment-illustration.jpg

Cell-Based Assays for the Tumor Microenvironment

Our immuno-oncology platform combines cancer cell-based assays for every cell in the tumor microenvironment with in vivo efficacy models to fully characterize your therapy for an accelerated journey to the clinic. Download the poster


Have another question or need advice on which model is right for you?

Ask our experts

 

Frequently Asked Questions (FAQs) in Cancer Cell-based Assays